> Epeius Biotechnologies will present the clinical results of a study entitled "A Phase I/II Study of Intravenous Rexin-G and Reximmune-C for Cancer Immunotherapy: The GeneVieve Protocol" at the ASCO Annual Meeting. Rexin-G and Reximmune-C are tumor-targeted retrovectors bearing a cytocidal anti-cyclin G1 construct and a controllable GM-CSF expression construct, respectively. Release
> FDA has approved Roxro's Sprix nasal spray for the short‐term management of acute moderate to moderately severe pain that requires analgesia at the opioid level. Sprix is a prescription intranasal formulation of the analgesic ketorolac, a non‐steroidal anti‐inflammatory drug, designed to provide ambulatory patients with a convenient, potent, and fast‐acting option. Release
ell Therapeutics will present phase II trial study results at the ASCO meeting in Chicago on June 6. The trial studied Opaxio, a biologically enhanced paclitaxel, administered in combination with standard cisplatin and concurrent radiation in patients with cancer of the lower esophagus. Opaxio is an investigational, biologically enhanced, chemotherapeutic that links paclitaxel, the active ingredient in Taxol, to a biodegradable polyglutamate polymer, which results in a new chemical entity. Release
> Pro-Pharmaceuticals, will submit a Phase III trial design for Davanat to the FDA during the second half of 2010. Davanat is a polysaccharide polymer that targets Galectin receptors, which peer-reviewed studies have demonstrated play important enabling roles in cancer, including tumor cell survival, angiogenesis, tumor metastasis and tumor invisibility to the immune system. Release
> Alkermes' supplemental NDA for Vivitrol for opioid dependence has been designated a priority review by the FDA. Vivitrol's proprietary Medisorb drug delivery technology enables the medication to be gradually released into the body at a controlled rate over a one-month time period. Release